Related Experiment Video
Updated: Sep 24, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Genetics of Anthracycline-Associated Cardiotoxicity
Talal Khalid Al-Otaibi1, Benjamin Weitzman1, Usman A Tahir1
1CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Abstract:
Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated with increased risk of ACT has the potential for significant clinical impact to improve patient care. The goal of this review is to summarize the current evidence supporting genetic variants associated with ACT, identify gaps and limitations in current knowledge, and propose future directions for incorporating genetics into clinical practice for patients treated with anthracyclines. We will discuss mechanisms of ACT that could be illuminated by genetics and discuss clinical applications for the cardiologist/cardio-oncologist.
Related Concept Videos
Cancer Prevention
Some...
Mutagenicity and Carcinogenicity
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification

